AIM insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| KELLNER TED D Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | Other transactionFiling detailsSEC transaction code D Common Stock · Indirect ownership · By Kellner,Ted Combined Profit Sharing/Money Purchase Plan · Reported balance after transaction: 0 · Shares held by the Kellner, Ted Combined Profit Sharing/Money Purchase Plan, for which the reporting person serves as trustee. | 2026-11-18 | 2026-11-20 | 250 shares/units | SEC 4 | Follow |
| KELLNER TED D Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | Other transactionFiling detailsSEC transaction code D Common Stock · Indirect ownership · By Beta Fund Investment Club · Reported balance after transaction: 0 · Shares held by the Beta Fund Investment Club, for which the reporting person serves as the manager and is an investor. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. | 2026-11-18 | 2026-11-20 | 2,702 shares/units | SEC 4 | Follow |
| KELLNER TED D Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | Other transactionFiling detailsSEC transaction code D Common Stock · Indirect ownership · By Kelvest ILP · Reported balance after transaction: 19714 · Shares held by Kelvest I LP, for which the reporting person serves as Manager of T&M Partners LLC, General Partner of Kelvest I LP. | 2026-11-18 | 2026-11-20 | 14,574 shares/units | SEC 4 | Follow |
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 436095 · SEC code covers open-market or private transactions | 2026-11-19 | 2026-11-20 | ≈ $6,550.00 50,000 shares/units | SEC 4 | Follow |
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 386095 · SEC code covers open-market or private transactions | 2026-11-18 | 2026-11-18 | ≈ $2,680.00 20,000 shares/units | SEC 4 | Follow |
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 366095 · SEC code covers open-market or private transactions | 2026-11-16 | 2026-11-17 | ≈ $5,130.00 38,000 shares/units | SEC 4 | Follow |
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 328095 · SEC code covers open-market or private transactions | 2026-11-11 | 2026-11-13 | ≈ $5,215.00 35,000 shares/units | SEC 4 | Follow |
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 293095 · SEC code covers open-market or private transactions | 2026-11-10 | 2026-11-12 | ≈ $5,382.00 39,000 shares/units | SEC 4 | Follow |
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 254095 · SEC code covers open-market or private transactions | 2026-11-09 | 2026-11-10 | ≈ $5,070.28 31,298 shares/units | SEC 4 | Follow |
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 222797 · SEC code covers open-market or private transactions | 2026-11-06 | 2026-11-09 | ≈ $2,014.66 12,751 shares/units | SEC 4 | Follow |
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 210046 · SEC code covers open-market or private transactions | 2026-11-06 | 2026-11-06 | ≈ $3,166.64 20,299 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.